



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Fast, et al.
SERIAL NUMBER: 10/036,768 EXAMINER : Jennifer M. Kim
FILING DATE: November 6, 2001 ART UNIT : 1617
FOR: METHODS AND REAGENTS FOR EXTRACORPOREAL
IMMUNOMODULATORY THERAPY


Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants hereby make of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate), copies of which are enclosed.

This Supplemental Information Disclosure Statement is been filed to submit documents submitted in a previous Information Disclosure Statement. However, the Examiner indicated in the September 23, 2003 Office Action that the enclosed documents had not been matched to the file. No fee or certification is believed required. However, please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 Reference No. 18242-511 (VI-0008-P3).


Respectfully submitted,



David E. Johnson, Reg. No. 41,874
Attorney for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: January 23, 2004

Please type
plus sign (+)
in this box



PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number 10/036,768 Filing Date November 6, 2001 First Named Inventor Fast Group Art Unit 1617 Examiner Name Jennifer Kim Attorney Docket Number 18242-511 (VI-0008-P3)
---	--

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Richter et al. (1998). "Extracorporeal photopheresis in therapy-refractory disseminated discoid lupus erythematosus!" <i>Hautarzt</i> 49(6): 487-491.
	C2	Chapman (2000). "Progress in improving the pathogen safety of red cell concentrates" <i>Vox Sang</i> 78(2): 203-204.
	C3	Fast et al. (2000). "Treatment of human leukocytes with inactine™ results in loss of function and induction of apoptosis" <i>Blood</i> 96(11): 61A
	C4	Lobastov, A.E., (1983) "Use of ethylenimine dimer for the inactivation of infectious rhinotracheitis virus of cattle" <i>Probl. Virusol., Mol. Biol. Gistol. S-kh Zhivotn.</i> , 4-6.
	C5	Amor, S. and H.E. Webb, "Use of N-Acetyl ethylenimine [AEi] for the activation of Semliki Forest Virus <i>in vitro</i> " <i>J. Medical Virology</i> 19:367-376.
	C6	Zalesskaya, M.A., "Inactivation of viral genome by beta-propiolactone and ethylenimines using the cacteriophage MA-2 as an example", Russian State Library, Moscow, Russia (1991)
	C7	Budowsky, E.I., "Problems and prospects for preparation of killed antiviral vaccines" <i>Ad. Virus Res.</i> 39:255-90
	C8	Hassanain, M.M., "Preliminary findings for an inactivated African horsesickness vaccine using binary ethylenimine" <i>Revue Elev. Med. Vet. Pays Trop.</i> 45:231-234
	C9	Russian Patent: SU 1809836 A3
	C10	Budowsky, et al. "Inactivation of the phage MS2 Infectivity by the Action of Ethyleneimines" <i>Biorg. Khim.</i> 11:989-991 (1985)
	C11	Budowsky, et al "Principles of selective Inactivation of the viral genome; dependence of the rate of viral RNA modification on the number of protonizable groups on ethylenimine Oligomers" <i>Vaccine Res.</i> 5:29-39
	C12	Abstract No. S137-040, AABB Meeting, held in San Antonio, TX, Oct. 13-17, 2001 "Pen 110 Treatment is More Effective than Conventional Gamma Irradiation at Inhibiting Human Peripheral Blood Mononuclear Cell Function: In Vitro Studies".
	C13	Abstract No. SP 185, AABB Meeting, held in San Antonio, TX, Oct. 13-17, 2001 "Removal of White Blood Cell and Plasma Proteins from Leukofiltered Red Blood Cell Concentrates by INACTINE™ Pathogen Inactivation"
	C14	Seghatchian, M.J. et al. Abstract: "Transfusion-associated graft-versus-host disease: current concepts and future trends" <i>Transfus Sci</i> 1995, Jun; 16(2): 99-105.
	C15	Fast, L.D. Abstract: "Recipient CD8+ cells are responsible for the rapid elimination of allogenic donor lymphoid cells" <i>J Immunol</i> 1996 Dec 1; 157(11):4805-10.
	C16	Fast, L.D. et al. Abstract: "Immune responses to major histocompatibility complex homozygous lymphoid cells in murine F1 hybrid recipients: implications for transfusion-associated graft-versus-host disease" <i>Blood</i> 1995 Oct 15;86(8):3090-6.



OTHER PRIOR ART & PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C17	Fast, L.D. "In Vitro Characterization of a Murine Recipient Anti-Donor Effector Cell Responsible for the Development of Chronic Graft-Versus-Host Disease" <i>The Journal of Immunology</i> , Vol. 147, 1731-38. September 15, 1991.
	C18	Fast, L.D. "Recipient Elimination of Allogeneic Lymphoid Cells: donor CD4+ cells are effective alloantigen-presenting cells" <i>Blood</i> , 1 Aug 2000, pp 1144-49, Vol. 96, No. 3.
	C19	Grass, J.A. et al. "Prevention of transfusion-associated graft-versus-host disease by photochemical treatment" <i>Blood</i> 1999 May 1; 93(9):3140-7.
	C20	Yasuda, H et al. Abstract: <i>Mechanism of Transfusion-associated graft-versus host disease</i> " <i>Fukushima J. Med. Sci</i> 1993 Dec; 39(2): 69-75.
	C21	Tsvetkova, E.A. et al. "Principles of Selective Inactivation of a Viral Genome. Comparative Kinetic Study of Modification of the Viral RNA and Model Protein with Oligoaziridines" <i>Biochemistry (Moscow)</i> , Vol. 66. No. 8 pp. 875-884. Translated from <i>Biokhimiya</i> , Vol. 66 No. 8, 2001 pp. 1078-1088.
	C22	Kasermann, F. et al. "Virus Inactivation and Protein Modifications by Ethyleneimines" <i>Antiviral Research</i> 52 (2001) pp. 33-41.
	C23	International Search Report for PCT/US 01/49956. Mailed on July 23, 2002.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1877607v1